NTLA Competitors & Alternatives
Compare Intellia Therapeutics, Inc with similar stocks in the same industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
NTLA
Main Stock$13.15
Tradestie Score
60
Market Cap
$2.01B
Revenue Growth
0.5%
Analyst Upside
+81.4%
Top Competitors
19 stocks in IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
IDXX
Idexx Laboratories Inc
|
$670.46
|
$49.61B | 54.6 | 59 | Compare |
|
LNTH
Lantheus Holdings, Inc
|
$66.92
|
$3.51B | 27.5 | 57 | Compare |
|
QDEL
QuidelOrtho Corporation Common Stock
|
$27.17
|
$2.12B | - | 55 | Compare |
|
CLDX
Celldex Therapeutics, Inc
|
$24.60
|
$1.68B | - | 44 | Compare |
|
NNNN
Anbio Biotechnology Class A Ordinary Shares
|
$21.91
|
$1.53B | 321.5 | 41 | Compare |
|
NEOG
Neogen Corp
|
$10.22
|
$1.26B | - | 61 | Compare |
|
MYGN
Myriad Genetics Inc
|
$5.62
|
$719.23M | - | 54 | Compare |
|
TKNO
Alpha Teknova, Inc. Common Stock
|
$2.42
|
$340.89M | - | 36 | Compare |
|
ACHV
Achieve Life Sciences, Inc.
|
$4.18
|
$158.43M | - | 47 | Compare |
|
IMDX
Insight Molecular Diagnostics Inc. Common Stock
|
$6.52
|
$94.16M | - | 52 | Compare |
More NTLA Analysis
Data updated: Jan 31, 2026 | Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (SIC 2835)
19 stocks in this industry